CHRNA7 and schizophrenia: However, a recent meta-analysis by Recio-Barbero et al. (81) points out that the current evidence of effects of administering α7-nAChR agonists for schizophrenia—as an add-on to antipsychotic treatment in tackling cognitive and negative symptoms—is too weak to consider as an effective treatment approach.